C11498: Effective Treatment of Acute Diarrhea Using a Novel Peptide Modification
Novelty:
A peptide derived from the Sodium-Hydrogen Exchanger-3 (NHE-3) protein that increases sodium absorption in the intestine, aiding rehydration and can be used as a therapeutic for acute diarrhea.
Value Proposition:
The Center for Disease Control recommends that currently marketed medications for diarrhea should not be used in cases of acute diarrhea. The peptide therapy described in this invention fills a critical gap in treatment options, particularly for pediatric patients who are most susceptible to acute diarrhea. Other advantages include:
• Enhanced effects of oral rehydration, which is the preferred, non-invasive method.
• Can be used as a therapy for both chronic and acute dehydration.
• Requires minimal concentrations to alter NHE-3 channel function in intestine.
• Proof of concept in In vivo model showed sodium concentrations and renal function remained stable.
Technical Details:
Johns Hopkins and Penn State University researchers have discovered a novel peptide derived from the NHE-3 ion channel in the human rectum which acts as a rehydration treatment for acute diarrhea and renal dysfunction. Specifically, this peptide assists with re-activating the NHE-3 protein and increases sodium absorption by reducing inhibition of the channel by calcium ions. This channel is used in sodium regulation in the human intestine and maintains calcium ion balance to retain normal renal function.
Looking for Partners:
To develop and commercialize the technology as a therapeutic protein for use in cases of acute diarrhea.
Stage of Development:
Pre-clinical
Data Availability:
Under CDA/NDA
Publications/Associated Cases:
